Babies born to moms who were in hurricanes during pregnancy have higher rates of health problems at birth, according to a working paper issued by the National Bureau of Economic Research.
The United States Food and Drug Administration (FDA), under its priority review program, recently approved PerjetaTM (pertuzumab), a HER2/neu receptor antagonist indicated in combination with HerceptinR (trastuzumab), another HER2 therapy, and docetaxel for treatment of HER2-positive metastatic breast cancer (BCa) in women who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
HMG-CoA reductase inhibitors, commonly referred to as statins, have gained popularity for their ability to effectively lower cholesterol levels in patients with CV disease, but new roles for statins may be on the horizon.
Women prescribed penicillins, erythromycins, and cephalosporins for bacterial infections during their first trimester may be reassured that these ntibacterial agents are not significantly associated with birth defects, new research shows.
After a priority review, the US Food and Drug Administration has approved Xanodyne Pharmaceuticals' formulation of tranexamic acid tablets (Lysteda) for the treatment of cyclic menorrhagia.
After a Canadian law mandating the fortification of flour and pasta products with folate went into effect in 1998, the birth prevalence of severe congenital defects has decreased in Quebec, according to a study published online May 12 in BMJ.
Data on smoking cessation medication in pregnancy are sparse and safety of drugs in pregnancy is unknown.
Adding the anthracycline epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) is superior to CMF alone as adjuvant therapy for early breast cancer, regardless of estrogen-receptor status, tumor grade, or patient age.
To guide health-care providers about the role of calcium in peri-and postmenopausal women, The North American Menopause Society recently developed an evidence-based statement.
A US Magistrate Judge ruled in November that the Center for Reproductive Rights can subpoena White House documents as part of its lawsuit against the Food and Drug Administration. The center is pursuing a lawsuit to ensure that Plan B is made widely available over the counter to women of all ages. (In August 2006, the FDA approved Plan B without a prescription, but only for women 18 years and older and only behind the pharmacy counter.)